Yes, the risk has decreased again.
But our P2 EMD AML trials in Australia and Europe are fully funded. So I'm not convinced that RAC are looking for a partner for EMD AML yet, other than for Inqovi supply.
Maybe for the US EMD AML P2 trial.
There won't be a P3 because of 505(b)(2).
Ann: Zantrene highly effective in EMD AML Mouse Model, page-52
-
- There are more pages in this discussion • 64 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.44 |
Change
0.040(2.86%) |
Mkt cap ! $245.3M | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.49 | $1.41 | $101.7K | 69.88K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9216 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.47 | 7767 | 2 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |